Settled
Do SGLT2 inhibitors improve lipids versus placebo?
Mostly studied in coronary & atherosclerotic disease. Also asked against other treatments.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Very likely. So far, repeated by independent trials.
NoUnsureYes
- Belief
- 1.00 (range 0.85–1.00)
- Trials for
- 2
- Trials against
- 0
- Inconclusive
- 4
Already under way
- Effects of SGLT2 Inhibitors on Coronary Atherosclerosis Progression in Diabetes Mediated by Perivascular Adipose Tissue: The SCOPE TrialNCT07614230 · recruiting · started 2026
- A Randomized, Open-label, Clinical Trial Evaluating the Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease…NCT07254572 · recruiting · started 2025
- GLP-1 and Antidiabetic SGLT2 Agents for Myocardial Infarction and Ultrasensitive Inflammatory Surveillance: An Open-Label Pilot StudyNCT07295223 · recruiting · started 2025
- Epicardial Cardiac Fat Comparative TrialNCT07297589 · recruiting · started 2025
- Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 DiabetesNCT06082063 · recruiting · started 2024
The evidence so far
- Registered trials
- 137
- With posted results
- 25
- Published papers
- 5
Of 45 decided analyses: 23 favor sglt2 inhibitors, 21 find no difference, 1 favor the comparator.
Papers
- Comparison of the effects of empagliflozin and sitagliptin, as an add-on to metformin, on cardio-metabolic and glycemic parameters of patients with type 2 diabetes mellitus: a randomized, double-blind clinical trial.Trial report · 2025
- Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials.Meta-analysis / systematic review · 2018
- Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.Meta-analysis / systematic review · 2017
- Efficacy & safety of sodium-glucose cotransporter-2 inhibitors in polycystic ovary syndrome: A meta-analysis with trial sequential analysis.Meta-analysis / systematic review · 2025
- Comparative effects of empagliflozin and metformin on metabolic dysfunction in polycystic ovary syndrome, a double blinded randomized control feasibility trial.Trial report · 2025
Trials
- A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes MellitusNCT01032629 · 10 posted results
- A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Pioglitazone TherapyNCT01106690 · 4 posted results
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin as Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and ExerciseNCT01081834 · 6 posted results
- A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin MonotherapyNCT01106677 · 10 posted results
- A Randomized, Double-Blind, 5-Arm, Parallel-Group, 26-Week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in Combination With Metformin as Initial Combination Therapy in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and ExerciseNCT01809327 · 4 posted results
- A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea TherapyNCT01106625 · 4 posted results
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering TherapyNCT01106651 · 4 posted results
- Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With PrediabetesNCT02700334 · 3 posted results